Photo from wikipedia
Key Points Question How have antiviral agents and monoclonal antibodies for mild to moderate COVID-19 been used in the Veterans Affairs health care system? Findings In this cohort study of… Click to show full abstract
Key Points Question How have antiviral agents and monoclonal antibodies for mild to moderate COVID-19 been used in the Veterans Affairs health care system? Findings In this cohort study of 111 717 outpatient US veterans with clinical risk factors for severe COVID-19 who tested positive for SARS-CoV-2 during January and February 2022, 4233 (3.8%) received outpatient pharmacotherapy. Black veterans and Hispanic veterans were less likely to receive treatment, whereas older veterans with a higher number of underlying conditions were more likely to receive treatment. Meaning These findings suggest that during a 2-month period when 4 anti–SARS-CoV-2 pharmacotherapies were authorized for use, few eligible veterans received treatment.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!